Drug
Humanized Anti Gd2 Antibody
Humanized Anti Gd2 Antibody: highest development phase Phase 2, developed by Y-mAbs Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Y-mAbs Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| humanized anti-GD2 antibody NCT02502786 | Phase 2 | Recurrent Osteosarcoma |
Latest
No recent events.
Follow Humanized Anti Gd2 Antibody on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.